Author:
Zinner Ralph G.,Obasaju Coleman K.,Spigel David R.,Weaver Robert W.,Beck J. Thaddeus,Waterhouse David M.,Modiano Manuel R.,Hrinczenko Borys,Nikolinakos Petros G.,Liu Jingyi,Koustenis Andrew G.,Winfree Katherine B.,Melemed Symantha A.,Guba Susan C.,Ortuzar Waldo I.,Desaiah Durisala,Treat Joseph A.,Govindan Ramaswamy,Ross Helen J.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference40 articles.
1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013
2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008
3. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non–small-cell lung cancer (NSCLC);Obasaju;J Clin Oncol,2009
4. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?;Grilli;J Clin Oncol,1993
5. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature;Marino;Chest,1994